Table 2. Prevalence and distribution of serological markers of Parvovirus B19 among sickle cell anemia (SCA) patients and controls.
| Parvovirus B19 Serological markers ˆ | SCA Patients [% (95% CI)] |
Non-SCA Control % (95% CI) |
Overall population |
|||||||
| Steady(N = 48) | Unsteady (N = 25) | Total (N = 73) | RR (95% CI) ˆ | (N = 81) | OR (95% CI) | P-value* | (N = 154) | |||
| IgM | 14.6 (4.6-24.6) | 24 (7.3-40.7)b | 17.8 (9-26.6) | 1.65 (0.62-4.37) | 11.1 (4.3-17.9) | 1.73 (0.64-4.77) | 0.24 | 14.3 (8.8-19.8) | ||
| IgG | 68.8 (55.7-81.9) | 48 (26.4-67.6)b | 61.6 (50.4-72.8) | 0.70 (0.45-1.10) | 64.2 (53.8-74.6) | 0.90 (0.44-1.82) | 0.74 | 62.9 (55.3-70.5) | ||
| IgM+IgG | 4.2 (1.5-9.9) | 12 (0.7-24.7)b | 6.8 (1-12.6) | 2.70 (0.48-15.1) | 0 (0) | ND | 0.02 | 3.2 (0.4-6) | ||
| Seronegative | 12.4 (3.1-21.9) | 16 (1.6-30.4)b | 13.8 (5.8-21.6) | 1.28 (0.40-4.12) | 24.7 (17.7-37.1) | 0.48 (0.19-1.2) | 0.09 | 19.5 (13.2-25.8) | ||
Data are percentage (95% Confidence interval, CI) of cases with parvovirus B19 serological markers. bP > 0.05 (Steady vs. Unsteady SCA patients); ˆ Relative risk (95% CI) values of steady state SCA patients compared to their unsteady state counterparts. *P-value (chi-square or Fischer exact test) of comparison between the SCA patients (Total) and non-SCA control. ˆ P < 0.05 (SCA vs. non-SCA for total frequency of IgM)-χ2 test. P < 0.05 was considered to be significant.